Correlative studies that performed immunohistochemistry (IHC) on tissue biopsies suggest that PD-L1 expression observed on tumor-infiltrating immune cells or on cancer cells could serve as a predictive marker for PD-1 blockade treatment, resulting in the development of complementary or companion diagnostics for some treatment indications [18]. Here, CD274 is linked to neoplasm.